TPI to Host Second Quarter of Fiscal Year 2013 Earnings Conference Call on Thursday, February 14, 2013 at 8:30 a.m. ET
CHENGDU, China, Jan. 31, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2013 ending December 31, 2012 to be held at 8:30 a.m. ET on Thursday, February 14, 2013.
Interested parties may access the call by dialing
|
Toll free: |
1-877-941-2068 |
|
International: |
1-480-629-9712 |
The conference ID is 4594892. It is advisable to dial in approximately 5 minutes prior to the start of the call.
A replay will be available by calling
|
Toll free: |
1-877-870-5176 |
|
International: |
1-858-384-5517 |
|
From: |
02/14/13 @ 11:30 am ET |
|
To: |
02/28/13 @ 11:59 pm ET |
|
Replay Pin Number: |
4594892 |
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=103373
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com , or email: ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
SOURCE Tianyin Pharmaceutical Co., Inc.
RELATED LINKS
http://www.tianyinpharma.com
http://public.viavid.com/index.php?id=103373
More by this Source
TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
Feb 15, 2013, 23:09 ET
TPI Reports Second Quarter Fiscal Year 2013 Financial Results
Feb 14, 2013, 05:55 ET
TPI Presents at the Sixth Annual OneMedForum on January 8-9, 2013 at San Francisco
Jan 02, 2013, 14:23 ET
Featured Video
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.





